A Phase 2 interventional study of Belumosudil and BSC in Idiopathic Pulmonary Fibrosis, sponsored by Kadmon Corporation, LLC. Completed at 10 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-09-08.
Sponsored by Kadmon Corporation, LLC (part of Sanofi) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 236 studies in Idiopathic Pulmonary Fibrosis with a site in United States — 37 open to participants now, 51 under way, 8 of them phase 3. Idiopathic Pulmonary Fibrosis · United States.
Among the 236 studies in Idiopathic Pulmonary Fibrosis with a site in United States, this one is the 88th largest by enrollment of the 188 interventional ones that give a count, is one of 11 that started in 2016, is one of 82 in phase 2, and was the 99th registered.
577 studies on the registry are indexed under Idiopathic Pulmonary Fibrosis; 124 are open to participants now.
Browse Idiopathic Pulmonary Fibrosis studies →37 of the 236 studies in Idiopathic Pulmonary Fibrosis with a site in United States are open now. Recruiting first, the newest first:
University of California, San Francisco · Sites in United States
Ages 18+
Oorja Bio, Inc. · Sites in United States
Ages 40+
Trevi Therapeutics · Sites in United States
Ages 40+
Joseph C. Wu · Sites in United States
Ages 40+
Chiesi Farmaceutici S.p.A. · Sites in United States, North Macedonia, Korea, Republic of and 1 more country
Ages 40+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 86 Idiopathic Pulmonary Fibrosis studies recruiting now, 56 (65%) set no upper age limit and 8 (9%) stop at 75 or younger; 3 take children under 18; 15 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
236 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 44 · Phase 2 89 · Phase 3 39 · Phase 4 6
First in 1999; this study’s year is marked. 11 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 76 is above the median of 55 across 390 interventional studies indexed under Idiopathic Pulmonary Fibrosis.
Median enrollment 61 across the 188 interventional studies, 320 across the 45 observational. Of the 170 that completed or were terminated, 85 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
134 of 236 have an industry lead sponsor. The 10 most frequent:
This study is registered under Kadmon Corporation, LLC, one of the names counted as Sanofi. Under that name alone:
Kadmon Corporation, LLC is the lead sponsor of 20 studies on the registry; none are open to participants now.
Sanofi has 4 studies filed under Idiopathic Pulmonary Fibrosis — fewer than ten, so there is no comparison to draw.
15 of the studies in Idiopathic Pulmonary Fibrosis with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06238622Phase 3Boehringer IngelheimA Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast | 2027-04-28 |
| NCT07868419Phase 3Trevi TherapeuticsIdiopathic Pulmonary Fibrosis (IPF)-Related Chronic Cough Reduction With Nalbuphine (NAL) Extended-Release (ER) Tablets | 2027-08 |
| NCT06736990Calluna Pharma ASA Phase 2 Study of CAL101 in Patients With Idiopathic Pulmonary Fibrosis | 2026-11 |
| NCT06853145University of VirginiaHyperpolarized Xenon-129 MRI in Idiopathic Pulmonary Fibrosis | 2026-12 |
| NCT03478553University of Colorado, DenverThe Genetics of Pulmonary Fibrosis | 2026-12-31 |
Add all 15 to your calendar (.ics) → With an account.
Among the 236 studies in Idiopathic Pulmonary Fibrosis with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This Phase 2 study is to be conducted to evaluate the safety, tolerability, and activity of 400 mg of belumosudil orally (PO) once-daily (QD) compared to Best Supportive Care (BSC) in male and postmenopausal/surgically sterilized female subjects with Idiopathic Pulmonary Fibrosis (IPF). The primary objectives are to evaluate the:
Study KD025-207 is a Phase 2, randomized, 2-part, open-label, crossover study in subjects with IPF.
The purpose of the study is to evaluate the safety, tolerability, and activity of 400 mg of belumosudil administered orally (PO) every day (QD) compared to Best Standard of Care (BSC) in subjects with IPF who have previously been treated with or declined treatment with pirfenidone or nintedanib.
The primary objectives are to evaluate the change in Forced Vital Capacity (FVC), and the safety and tolerability from baseline to 24 weeks in subjects with IPF after dosing with belumosudil 400 mg PO QD compared to BSC.
Part 1: Randomized, Open-label for 24 Weeks
Approximately 81 eligible subjects with IPF are to be enrolled, in 10 to 15 sites, and randomized in a 2:1 ratio (belumosudil:BSC) to 1 of the following 2 groups:
The study plan is for 54 subjects to be entered into the Belumosudil-R Treatment Group and 27 subjects into the BSC-R Treatment Group. This sample size provides over 90% power at the 2-sided 0.05 significance level to detect a 20% difference between treatment groups at 24 weeks in percentage change from baseline in FVC assuming a standard deviation (SD) in percentage change from baseline in FVC of 17%. The sample size of 54 subjects receiving belumosudil provides over 90% probability of ≥ 1 subject in the study experiencing an AE that had an underlying rate of ≥ 5%.
Part 2: Continuation of Belumosudil Therapy or Crossover to Belumosudil Therapy Subjects in the Belumosudil-R group who complete 24 weeks of treatment with belumosudil 400 mg PO QD have the option of continuing therapy with belumosudil 400 mg PO QD up to an additional 72 weeks if there are no safety signals and if clinical progress continues. No subject in the Belumosudil-R group is to be permitted to receive therapy with belumosudil greater than a total of 96 weeks.
Subjects in control group BSC-R who complete 24 weeks of BSC have the option of crossing over to therapy with belumosudil 400 mg PO QD for up to 96 weeks if there are no safety signals and if clinical progress continues. No subject in control group BSC-R is to be permitted to receive belumosudil 400 mg PO QD therapy greater than 96 weeks.
Follow-up Period:
Follow-up Visits are to occur 30 days (± 3 days) after the last dose of belumosudil during which subjects are to undergo safety assessments. (A Follow-up Visit is not necessary for subjects receiving BSC.)
Duration of Study for Individual Subjects:
Efficacy Assessments
Biomarker Assessments
Safety Assessments
Analyses
Efficacy and safety are to be analyzed at the end of Part 1 (Week 24) and for the Entire Treatment Period (Parts 1 and 2). Analyses of study subjects are to be grouped and defined as follows:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
A subject had to meet all of the following criteria to be eligible for the study:
Men with partners of willing to use 2 medically acceptable methods of during the trial and for 3 months after the last dose of study drug. Effective birth control includes:
Have adequate bone marrow function:
Exclusion Criteria:
A subject who met any of the following criteria was ineligible for the study:
Chronic treatment with the following drugs within 4 weeks of study entry and during the study:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects receive two 200 mg tablets of belumosudil (400 mg) PO QD for 24 weeks. Subjects may also continue treatment with belumosudil 400 mg PO QD after 24 weeks. No subject may receive more than 96 weeks of treatment with belumosudil
Drug: Belumosudil
Subjects receive best supportive care as determined by the physician. Subjects may later crossover to treatment with belumosudil 400 mg PO QD. No subject may receive more than 96 weeks of treatment with belumosudil.
Other: BSC
Also known as: KD025, SLx-2119
Treatment/drug as determined by each subject's prescribing physician
Also known as: Best standard of care
Efficacy: Mean Changes in FVC From Baseline to Week 24
Changes in the mean Forced Vital Capacity (FVC) from baseline at Week 24. Normal FVC-- Healthy males 20 to 60 years: 4.75 to 5.5 L; healthy females 20 to 60 years: 3.25 to 3.75 L
Time frame: 24 weeks
Efficacy: Mean Changes in FVC% Predicted From Baseline at Week 24
Changes in the mean Forced Vital Capacity (FVC)% Predicted from baseline at Week 24. Normal FVC%: 80% to 120%
Time frame: 24 weeks
Safety: Percentages of Subjects With Non-serious TEAEs and Relationship to Study Treatment
Percentage of subjects with non-serious TEAEs by relationship to treatment with belumosudil, BSC, or belumosudil and BSC. Severity of TEAEs were measured using the Common Terminology Criteria for Adverse Events (CTCAE) version 22.1 (Grade 1 = mild; Grade 2 = moderate; Grade 3 = severe; Grade 4 = life-threatening; Grade 5 = fatal).
Time frame: Up to 96 weeks (Weeks 24, 48, and 96) of treatment with belumosudil. Subjects randomized to BSC had the option of crossing over at 24 weeks.
Safety: Percentages of Subjects With SAEs Related to Study Treatment
Percentage of subjects with serious TEAEs by relationship to treatment with belumosudil and/or BSC. Investigators assessed whether events were related to treatment as possibly, probably, or definitely related.
Time frame: Up to 96 weeks (Weeks 24, 48, and 96) of treatment with belumosudil. Subjects randomized to BSC and crossing over also up to 24 weeks of BSC.
Safety: Percentages of Subjects With TEAEs Leading to Discontinuation of Treatment With Belumosudil
Percentage of subjects with treatment-emergent adverse events (TEAEs) leading to subjects discontinuing from treatment. Investigators assessed whether TEAEs leading to discontinuation were related to study drug (possibly, probably, or definitely), belumosudil 400 mg PO QD.
Time frame: Up to 96 weeks (Weeks 24, 48, and 96) of treatment with belumosudil
Safety: Percentages of Subjects With Deaths Related to Study Treatment
Percentage of subjects with deaths by relationship to treatment with belumosudil, BSC, or belumosudil and BSC. Investigators assessed whether events were related to treatment as possibly, probably, or definitely related.
Time frame: Up to 96 weeks (Weeks 24, 8, and 96) of treatment with belumosudil. Subjects randomized to BSC also had the option of crossing over to treatment with belumosudil at 24 weeks.
Efficacy: Mean Changes in FVC From Baseline at Week 24 by GAP Stage and by Use of Pirfenidone or Nintedanib--
Changes in the mean Forced Vital Capacities (FVC) at Week 24 by Gender/Age/Physiology (GAP) Stage and by the previous use of pirfenidone and/or nintedanib prior to the study for Belumosudil-WC compared to BSC-NC. Normal FVC--Healthy males 20 to 60 years: 4.75 to 5.5 L; healthy famles 20 to 60 years: 3.25 to 3.75 L GAP is measured by points as follows: (G) Gender: Female = 0 points; Male = 1 point (A) Age: ≤ 60 years = 0 points; 61-65 years = 1 point; \> 65 years = 2 points (P) Physiology: * FVC% Predicted: \> 75% = 0 points; 50-75% = 1 point; ≤ 50% = 2 points * DLCO% (diffusing lung capacity of carbon monoxide by % predicted) Predicted: \> 55% = 0 points; 36-55% = 1 point, ≤ 35% = 2 points; cannot perform = 3 points GAP Stage: * Stage I Index = 0 to 3 points * Stage II Index= 4 to 5 points * Stage III Index = 6 to 8 points
Time frame: 24 weeks
Efficacy: Mean Changes in FVC From Baseline at Week 48, Week 96, and EOT
Changes in the mean Forced Vital Capacity (FVC) from baseline at Weeks 48 and 96, and End-of-Treatment (EOT) Normal FVC: Healthy males 20 to 60 years: 4.75 to 5.25 L; healthy females 20 to 60 years: 3.25 to 3.75 L
Time frame: Up to 96 weeks (Weeks 24, 48, and 96)
Efficacy: Mean Change in Mean FEV1/FVC Ratio From Baseline at Weeks 24, 48, and 96 and EOT
Change in the mean ratio of Forced Expiratory Volume in 1 Second (FEV1) divided by the Forced Vital Capacity (FVC) at Week 24, Week 48, Week 96, and End-of-Treatment (EOT) Normal FEV1: 80% to 120% FEV1/FVC = Within 5% of predicted ratio
Time frame: Up to 96 weeks (Weeks 24, 48, and 96)
Efficacy: Mean Changes in FVC% Predicted at Week 24 by GAP Stage and by Use of Pirfenidone or Nintedanib--
Changes in the mean Forced Vital Capacities (FVC)% Predicted at Week 24 by Gender/Age/Physiology (GAP) Stage and by the previous use of pirfenidone and/or nintedanib prior to the study for Belumosudil-WC compared to BSC-NC. GAP is measured by points as follows: (G) Gender: Female = 0 points; Male = 1 point (A) Age: ≤ 60 years = 0 points; 61-65 years = 1 point; \> 65 years = 2 points (P) Physiology: * FVC% Predicted: \> 75% = 0 points; 50-75% = 1 point; ≤ 50% = 2 points * DLCO% (diffusing lung capacity of carbon monoxide by % predicted) Predicted: \> 55% = 0 points; 36-55% = 1 point, ≤ 35% = 2 points; cannot perform = 3 points GAP Stage: * Stage I = 0 to 3 points * Stage II = 4 to 5 points * Stage III = 6 to 8 points
Time frame: 24 weeks
Efficacy: Percentages of Subjects With Decrease ≥ 5% in FVC% Predicted From Baseline at Weeks 24, 48, and 96
Percentage of subjects exhibiting at least a 5% decrease in Forced Vital Capacity (FVC)% Predicted from baseline at Week 24, at Week 48, and at Week 96
Time frame: Up to 96 weeks (Weeks 24, 48, and 96)
Efficacy: Percentage of Subjects With Decrease ≥ 10% in FVC% Predicted at Weeks 24, 48, and 96
Percentage of subjects who exhibited at least a 10% decrease in Forced Vital Capacity (FVC)% Predicted from baseline at Week 24, at Week 48, and at Week 96
Time frame: Up to 96 weeks (Weeks 24, 48, and 96)
Efficacy: Mean Change in 6MWD at Weeks 24, 48, and 96
The mean change in the 6-mile Walking Distance (6MWD), i.e., the distance a subject can walk in 6 minutes, from baseline to Week 24, to Week 48, and to Week 96. Positive change = improvement; negative change = worsening
Time frame: Up to 96 weeks (Weeks 24, 48, and 96)
Efficacy: Percentages of Subjects With ≥ 50 Meter Improvement in 6MWD at Weeks 24, 48, and 96
The percentage of subjects who have at least a 50 meter improvement in the 6-mile Walking Distance (6MWD), i.e., the distance a subject can walk in 6 minutes, from baseline to Week 24, Week 48, and Week 96.
Time frame: Up to 96 weeks (Weeks 24, 48, and 96)
Efficacy: Mean Changes in DLCO (%) at Weeks 24, 48, and 96
The diffusing capacity for carbon dioxide (DLCO) is a measure of the conductance of gas transfer from inspired gas to the red blood cells. Normal DLCO is \> 75% of predicted up to 140%. Severity is generally rated as: * Mild: 60% to lower limit of normal * Moderate: 40% to 60% * Severe: \< 40%
Time frame: Up to 96 weeks (Weeks 24, 48, and 96)
Efficacy: Percentages of Subjects With Change From Baseline in DLCO (%) ≤ -15% at Weeks 24, 48, and 96
Percentage of the number of subjects who exhibit less than a -15% decrease in diffusing capacity of carbon monoxide (DLCO), measured as % from baseline at Week 24, Week 48, and Week 96 The diffusing capacity for carbon dioxide (DLCO) is a measure of the conductance of gas transfer from inspired gas to the red blood cells. Normal DLCO is \> 75% of predicted up to 140%. Severity is generally rated as: * Mild: 60% to lower limit of normal * Moderate: 40% to 60% * Severe: \< 40%
Time frame: Up to 96 weeks (Weeks 24, 48, and 96)
Efficacy: Mean Changes in Total Lung Fibrosis Score, by HRCT, From Baseline at Weeks 24, 48, and 96
The change in Total Lung Fibrosis mean score from baseline at Weeks 24, 48, and 96. Measurements using quantitative high-resolution computerized tomography (HRCT) and include (1) extent of fibrotic abnormality; (2) fibrosis score; (3) ground glass opacity; (4) honeycombing score; (5) kurtosis of lung voxel intensity; (6) skewness of lung voxel intensity; (7) standard deviation of voxel; (8) CT total lung volume; (9) normal lung; (10) reticular score; and (11) evaluation of change on sequential scans. The Quantitative Lung Fibrosis (QLF) score measures the extent of reticular patterns with architectural distortion due to fibrosis using a support vector machine classifier. Range: 0 to 100. Higher scores imply greater impairment.
Time frame: Up to 96 weeks (Weeks 24, 48, and 96)
Efficacy: Categorical Changes in Lung Fibrosis as Observed by Sequential Scans of Radiologist Visual Assessment, From Baseline at Weeks 24, 48, and 96
The categorical changes of lung fibrosis using subjective visual assessments by radiologists from sequential scans at baseline, Week 24, Week 48, and Week 96. Changes were categorized as: (1) much better; (2) slightly better; (3) same; (4) slightly worse; and (5) much worse. This categorization is simplified as Better (Much or Slightly); Same; and Worse (Slightly or Much).
Time frame: Up to 96 weeks (Weeks 24, 48, and 96)
Efficacy: Changes in Mean DTA Lung Fibrosis Score, by Radiologist Visual Assessment, From Baseline at Weeks 24, 48, and 96
The change in Data-driven Texture Analysis (DTA) Lung Fibrosis mean score using sequential scans from Radiologist's Visual Reads from baseline to Weeks 24, 48, and 96. The change in DTA Lung Fibrosis mean score was measured using sequential scans from Radiologist's Visual Reads from baseline at Weeks 24, 48, and 96. DTA fibrosis score was computed as the number of Region of Interests (ROIs) classified as fibrotic divided by the total number of ROIs sampled from the lung segmentation volume. The DTA fibrosis score ranged from 0 - 100%, where higher scores indicated worsening of disease.
Time frame: Up to 96 Weeks (Weeks 24, 48, and 96)
Efficacy: Event-free Probability of Acute Exacerbation of IPF
Acute exacerbation of IPF was defined by the following symptoms within 1 month that could not be explained by other reasons: (1) aggravated dyspnea; (2) newly discovered chest interstitial lung abnormality (by radiograph or HRCT); (3) SpO2 decrease to \< 88%. Acute exacerbation was diagnosed if Items #1 and #2 were present or if Items #1 and #3 were present and the following AEs did not occur: (A) any AE with the Preferred Term containing the word "infection" or "cardiac failure"; (B) pulmonary embolism; (C) pneumothorax.
Time frame: Up to 96 weeks (Weeks 24, 48, and 96)
Efficacy: Event-free Probability of Progression of IPF
Progression of IPF exacerbation was defined as the probability of a subject exhibiting IPF time from baseline to any of the following: (1) probability of first respiratory-related hospitalization; (2) probability of respiratory-related death; absolute decline in FVC% Predicted value of ≥ 10% vs. FVC %; probability of predicted value recorded at baseline; and (4) probability of absolute decline in DLCO, adjusted for hemoglobin (Hb), Percent of predicted value of ≥ 15% vs. DLCO at baseline. Subjects randomized to and received BSC were censored on crossover.
Time frame: Up to 96 weeks (Weeks 24, 48, and 96)
Efficacy: Event-free Probability of First Respiratory-related Hospitalization
Probability of first-related hospitalization defined as any AE where the high-level group term contained the terms "respiratory" and the AE resulted in a hospitalization. Subjects randomized and received BSC were censored on crossover. Note: The hazard ratios for Belumosudil-R vs. BSC-NC and for Belumosudil-WC vs. BSC-NC were not calculable.
Time frame: Up to 96 weeks (Weeks 24, 48, and 96)
Efficacy: Event-free Probability of Respiratory-related Death
Probability of respiratory-related death, defined as any AE where the high-level group term contained the term "respiratory" and the AE resulted in a death. Subjects randomized to and who received BSC were censored on crossover.
Time frame: Up to 96 weeks (Weeks 24, 48, and 96)
Efficacy: Mean Changes in SGRQ From Baseline at Weeks 24, 48 and 96
The St. George's Respiratory Questionnaire (SGRQ) is a disease-specific instrument designed to measure impact on overall health, daily life, and perceived well-being in subjects with obstructive airways disease consisting of 2 parts: (1) symptoms component (frequency \& severity) with a 3-month recall; and (2) activities that cause or are limited by breathlessness. Impact components (social functioning, psychological disturbances resulting from airways disease) refer to current state as the recall. Changes were assessed from baseline at Week 24, at Week 48, and at Week 96. The SGRQ scores range from 0 to 100, with higher scores indicating greater limitations. Based on empirical data and interviews with subjects, a mean change score of 4 units is associated with slightly efficacious treatment, 8 units for moderately efficacious change, and 12 units for very efficacious treatment
Time frame: Up to 96 weeks (Weeks 24, 48, and 96)
| Milestone | Belumosudil-R | BSC-R |
|---|---|---|
| Started | 52 | 24 |
| Treated | 51 | 24 |
| Completed | 51 | 18 |
| Not completed | 1 | 6 |
| Withdrew: Death | 0 | 1 |
| Withdrew: Cross-overed before initial treatment period (24 weeks) | 0 | 5 |
| Withdrew: Subject was randomized but did not receive treatment | 1 | 0 |
| Milestone | Belumosudil-R | BSC-R |
|---|---|---|
| Started | 51 | 17 |
| Completed | 23 | 3 |
| Not completed | 28 | 14 |
| Withdrew: Death | 7 | 2 |
| Withdrew: Lost to follow-up | 1 | 0 |
| Withdrew: Other | 10 | 6 |
| Withdrew: Withdrawal by subject | 10 | 6 |
Changes in the mean Forced Vital Capacity (FVC) from baseline at Week 24. Normal FVC-- Healthy males 20 to 60 years: 4.75 to 5.5 L; healthy females 20 to 60 years: 3.25 to 3.75 L
| mL | Belumosudil-R | BSC-R | Belumosudil-WC | BSC-NC | Total |
|---|---|---|---|---|---|
| Baseline | 2608.2 ± 829.6 | 2516.7 ± 741.8 | 2608.8 ± 840.4 | 2516.7 ± 741.8 | 2569.3 ± 794.3 |
| At Week 24 | 2626.8 ± 886.9 | 2438.1 ± 757.1 | 2617.4 ± 890.8 | 2436.8 ± 784.5 | 2533.7 ± 832.7 |
| Change at Week 24 | -115.8 ± 330.3 | -71.2 ± 254.2 | -110.8 ± 316.4 | -103.4 ± 225.0 | -99.5 ± 281.4 |
Changes in the mean Forced Vital Capacity (FVC)% Predicted from baseline at Week 24. Normal FVC%: 80% to 120%
| % of predicted | Belumosudil-R | BSC-R | Belumosudil-WC | BSC-NC | Total |
|---|---|---|---|---|---|
| Baseline | 69.61 ± 18.07 | 68.46 ± 15.63 | 69.73 ± 17.70 | 68.46 ± 15.63 | 69.19 ± 16.71 |
| At Week 24 | 69.71 ± 19.20 | 68.29 ± 13.41 | 69.96 ± 18.43 | 68.58 ± 13.98 | 69.24 ± 16.25 |
| Change at Week 24 | -2.82 ± 7.57 | -2.00 ± 7.36 | -2.66 ± 7.49 | -3.00 ± 6.41 | -2.58 ± 7.16 |
Percentage of subjects with non-serious TEAEs by relationship to treatment with belumosudil, BSC, or belumosudil and BSC. Severity of TEAEs were measured using the Common Terminology Criteria for Adverse Events (CTCAE) version 22.1 (Grade 1 = mild; Grade 2 = moderate; Grade 3 = severe; Grade 4 = life-threatening; Grade 5 = fatal).
| Participants | Belumosudil-R | BSC-R | Belumosudil-WC | BSC-NC | Total |
|---|---|---|---|---|---|
| TEAEs Related to Treatment (All Grades) | 23 | 9 | 32 | 2 | 32 |
| TEAEs Related to Treatment (Only Grades 3 & 4) | 2 | 0 | 2 | 0 | 2 |
Percentage of subjects with serious TEAEs by relationship to treatment with belumosudil and/or BSC. Investigators assessed whether events were related to treatment as possibly, probably, or definitely related.
| Participants | Belumosudil-R | BSC-R | Belumosudil-WC | BSC-NC | Total |
|---|---|---|---|---|---|
| Safety: Percentages of Subjects With SAEs Related to Study Treatment | 2 | 0 | 2 | 0 | 2 |
Percentage of subjects with treatment-emergent adverse events (TEAEs) leading to subjects discontinuing from treatment. Investigators assessed whether TEAEs leading to discontinuation were related to study drug (possibly, probably, or definitely), belumosudil 400 mg PO QD.
| Participants | Belumosudil-R | BSC-R | Belumosudil-WC | Total |
|---|---|---|---|---|
| All TEAEs Leading to Discontinuation | 14 | 8 | 22 | 22 |
| TEAEs Related to Belumosudil Leading to Study Discontinuation | 5 | 1 | 6 | 6 |
Percentage of subjects with deaths by relationship to treatment with belumosudil, BSC, or belumosudil and BSC. Investigators assessed whether events were related to treatment as possibly, probably, or definitely related.
| Participants | Belumosudil-R | BSC-R | Belumosudil-WC | BSC-NC | Total |
|---|---|---|---|---|---|
| Safety: Percentages of Subjects With Deaths Related to Study Treatment | 0 | 0 | 0 | 0 | 0 |
Changes in the mean Forced Vital Capacities (FVC) at Week 24 by Gender/Age/Physiology (GAP) Stage and by the previous use of pirfenidone and/or nintedanib prior to the study for Belumosudil-WC compared to BSC-NC. Normal FVC--Healthy males 20 to 60 years: 4.75 to 5.5 L; healthy famles 20 to 60 years: 3.25 to 3.75 L GAP is measured by points as follows: (G) Gender: Female = 0 points; Male = 1 point (A) Age: ≤ 60 years = 0 points; 61-65 years = 1 point; \> 65 years = 2 points (P) Physiology: * FVC% Predicted: \> 75% = 0 points; 50-75% = 1 point; ≤ 50% = 2 points * DLCO% (diffusing lung capacity of carbon monoxide by % predicted) Predicted: \> 55% = 0 points; 36-55% = 1 point, ≤ 35% = 2 points; cannot perform = 3 points GAP Stage: * Stage I Index = 0 to 3 points * Stage II Index= 4 to 5 points * Stage III Index = 6 to 8 points
| mL | Belumosudil-WC | BSC-NC |
|---|---|---|
| GAP Stage I | -117.65 (-324.28 to 88.98) | -156.50 (-355.39 to 42.40) |
| GAP Stage II | -219.90 (-416.20 to -23.60) | -179.94 (-444.35 to 84.47) |
| GAP Stage III | 101.95 (-1246.61 to 1450.50) | 7.79 (-1553.37 to 1568.95) |
| No Prior Use of Pirfenidone or Nintedanib | -80.34 (-190.81 to 30.14) | -46.21 (-167.93 to 75.51) |
Changes in the mean Forced Vital Capacity (FVC) from baseline at Weeks 48 and 96, and End-of-Treatment (EOT) Normal FVC: Healthy males 20 to 60 years: 4.75 to 5.25 L; healthy females 20 to 60 years: 3.25 to 3.75 L
| mL | Belumosudil-R | BSC-R | Belumosudil-WC | Total |
|---|---|---|---|---|
| Baseline | 2608.2 ± 829.6 | 2516.7 ± 741.8 | 2608.8 ± 840.4 | 2569.3 ± 794.3 |
| Change at Week 48 | -197.2 ± 331.5 | -82.5 ± 329.7 | -199.6 ± 366.1 | -177.8 ± 358.8 |
| Change at Week 96 | -141.0 ± 401.1 | -264.0 ± 896.0 | -122.2 ± 384.3 | -147.5 ± 492.3 |
| Change at EOT | -227.9 ± 367.7 | -110.7 ± 397.7 | -207.2 ± 353.7 | -180.9 ± 355.8 |
Change in the mean ratio of Forced Expiratory Volume in 1 Second (FEV1) divided by the Forced Vital Capacity (FVC) at Week 24, Week 48, Week 96, and End-of-Treatment (EOT) Normal FEV1: 80% to 120% FEV1/FVC = Within 5% of predicted ratio
| Units | Belumosudil-R | BSC-R | Belumosudil-WC | BSC-NC | Total |
|---|---|---|---|---|---|
| Baseline | 0.829 ± 0.0613 | 0.816 ± 0.0674 | 0.832 ± 0.0584 | 0.816 ± 0.0674 | 0.825 ± 0.0623 |
| Change at Week 24 | -0.006 ± 0.0444 | 0.013 ± 0.0310 | -0.005 ± 0.0410 | 0.016 ± 0.0311 | 0.004 ± 0.0378 |
| Change at Week 48 | 0.001 ± 0.0251 | -0.005 ± 0.0141 | -0.001 ± 0.0249 | — | -0.002 ± 0.0232 |
| Change at Week 96 | -0.012 ± 0.0420 | -0.014 ± 0.0378 | -0.012 ± 0.0402 | — | -0.012 ± 0.0391 |
| Change at EOT | -0.010 ± 0.0362 | 0.011 ± 0.0372 | -0.011 ± 0.0453 | -0.010 ± 0 | -0.007 ± 0.0436 |
Changes in the mean Forced Vital Capacities (FVC)% Predicted at Week 24 by Gender/Age/Physiology (GAP) Stage and by the previous use of pirfenidone and/or nintedanib prior to the study for Belumosudil-WC compared to BSC-NC. GAP is measured by points as follows: (G) Gender: Female = 0 points; Male = 1 point (A) Age: ≤ 60 years = 0 points; 61-65 years = 1 point; \> 65 years = 2 points (P) Physiology: * FVC% Predicted: \> 75% = 0 points; 50-75% = 1 point; ≤ 50% = 2 points * DLCO% (diffusing lung capacity of carbon monoxide by % predicted) Predicted: \> 55% = 0 points; 36-55% = 1 point, ≤ 35% = 2 points; cannot perform = 3 points GAP Stage: * Stage I = 0 to 3 points * Stage II = 4 to 5 points * Stage III = 6 to 8 points
| % of predicted | Belumosudil-WC | BSC-NC |
|---|---|---|
| GAP Stage I | -4.65 (-11.34 to 2.03) | -6.53 (-13.14 to 0.07) |
| GAP Stage II | -6.42 (-11.69 to -1.15) | -4.69 (-11.58 to 2.19) |
| GAP Stage III | 2.34 (-36.32 to 40.99) | -0.15 (-42.95 to 42.65) |
| Prior Use of Pirfenidone or Nintedanib | -6.20 (-58.23 to 45.82) | -14.91 (-92.49 to 62.68) |
Percentage of subjects exhibiting at least a 5% decrease in Forced Vital Capacity (FVC)% Predicted from baseline at Week 24, at Week 48, and at Week 96
| Participants | Belumosudil-R | BSC-R | Belumosudil-WC | BSC-NC | Total |
|---|---|---|---|---|---|
| At Week 24: Yes | 11 | 7 | 14 | 7 | 21 |
| At Week 24: No | 27 | 14 | 32 | 12 | 42 |
| At Week 48: Yes | 14 | 4 | 16 | — | 18 |
| At Week 48: No | 15 | 4 | 19 | — | 20 |
| At Week 96: Yes | 6 | 2 | 6 | — | 8 |
| At Week 96: No | 14 | 3 | 17 | — | 17 |
Percentage of subjects who exhibited at least a 10% decrease in Forced Vital Capacity (FVC)% Predicted from baseline at Week 24, at Week 48, and at Week 96
| Participants | Belumosudil-R | BSC-R | Belumosudil-WC | BSC-NC | Total |
|---|---|---|---|---|---|
| At Week 24: Yes | 5 | 4 | 6 | 4 | 10 |
| At Week 24: No | 33 | 17 | 40 | 15 | 50 |
| At Week 48: Yes | 7 | 1 | 9 | — | 10 |
| At Week 48: No | 22 | 7 | 26 | — | 30 |
| At Week 96: Yes | 5 | 2 | 5 | — | 7 |
| At Week 96: No | 15 | 3 | 18 | — | 18 |
The mean change in the 6-mile Walking Distance (6MWD), i.e., the distance a subject can walk in 6 minutes, from baseline to Week 24, to Week 48, and to Week 96. Positive change = improvement; negative change = worsening
| meters | Belumosudil-R | BSC-R | Belumosudil-WC | BSC-NC | Total |
|---|---|---|---|---|---|
| Baseline | 368.59 ± 168.84 | 349.25 ± 180.40 | 350.12 ± 168.88 | 323.11 ± 126.64 | 345.17 ± 163.88 |
| Change at Week 24 | -12.11 ± 101.78 | -16.60 ± 66.80 | 7.53 ± 177.88 | -0.77 ± 49.08 | -0.04 ± 140.22 |
| Change at Week 48 | -18.33 ± 102.45 | 119.00 ± 364.61 | -18.83 ± 95.33 | — | 6.23 ± 178.69 |
| Change at Week 96 | -23.06 ± 78.84 | -47.80 ± 69.80 | -20.98 ± 72.80 | — | -26.34 ± 71.60 |
The percentage of subjects who have at least a 50 meter improvement in the 6-mile Walking Distance (6MWD), i.e., the distance a subject can walk in 6 minutes, from baseline to Week 24, Week 48, and Week 96.
| Participants | Belumosudil-R | BSC-R | Belumosudil-WC | BSC-NC | Total |
|---|---|---|---|---|---|
| ≥ 50 Meter Improvement at Week 24: Yes | 6 | 4 | 8 | 2 | 11 |
| ≥ 50 Meter Improvement at Week 24: No | 31 | 16 | 37 | 11 | 48 |
| ≥ 50 Meter Improvement at Week 48: Yes | 6 | 2 | 8 | — | 10 |
| ≥ 50 Meter Improvement at Week 48: No | 24 | 6 | 28 | — | 32 |
| ≥ 50 Meter Improvement at Week 96: Yes | 5 | 2 | 5 | — | 7 |
| ≥ 50 Meter Improvement at Week 96: No | 12 | 3 | 15 | — | 15 |
The diffusing capacity for carbon dioxide (DLCO) is a measure of the conductance of gas transfer from inspired gas to the red blood cells. Normal DLCO is \> 75% of predicted up to 140%. Severity is generally rated as: * Mild: 60% to lower limit of normal * Moderate: 40% to 60% * Severe: \< 40%
| % of diffusing capacity of CO | Belumosudil-R | BSC-R | Belumosudil-WC | BSC-NC | Total |
|---|---|---|---|---|---|
| Baseline | 47.3 ± 11.7 | 47.3 ± 9.9 | 47.1 ± 12.0 | 48.0 ± 10.2 | 47.3 ± 11.1 |
| Change at Week 24 | -2.7 ± 9.5 | -3.8 ± 5.4 | -3.1 ± 9.3 | -4.5 ± 5.6 | -3.6 ± 7.7 |
| Change at Week 48 | -2.9 ± 8.3 | -7.1 ± 12.7 | -3.2 ± 8.0 | — | -3.9 ± 9.0 |
| Change at Week 96 | -4.2 ± 11.3 | -13.7 ± 17.7 | -6.0 ± 11.4 | — | -8.2 ± 13.4 |
Percentage of the number of subjects who exhibit less than a -15% decrease in diffusing capacity of carbon monoxide (DLCO), measured as % from baseline at Week 24, Week 48, and Week 96 The diffusing capacity for carbon dioxide (DLCO) is a measure of the conductance of gas transfer from inspired gas to the red blood cells. Normal DLCO is \> 75% of predicted up to 140%. Severity is generally rated as: * Mild: 60% to lower limit of normal * Moderate: 40% to 60% * Severe: \< 40%
| Participants | Belumosudil-R | BSC-R | Belumosudil-WC | BSC-NC | Total |
|---|---|---|---|---|---|
| Week 24 Change ≤ -15%: Yes | 7 | 7 | 10 | 6 | 16 |
| Week 24 Change ≤ -15%: No | 29 | 14 | 33 | 9 | 43 |
| Week 48 Change ≤ -15%: Yes | 10 | 4 | 11 | — | 14 |
| Week 48 Change ≤ -15%: No | 18 | 4 | 23 | — | 24 |
| Week 96 Change ≤ -15%: Yes | 3 | 4 | 5 | — | 7 |
| Week 96 Change ≤ -15%: No | 7 | 1 | 8 | — | 8 |
The change in Total Lung Fibrosis mean score from baseline at Weeks 24, 48, and 96. Measurements using quantitative high-resolution computerized tomography (HRCT) and include (1) extent of fibrotic abnormality; (2) fibrosis score; (3) ground glass opacity; (4) honeycombing score; (5) kurtosis of lung voxel intensity; (6) skewness of lung voxel intensity; (7) standard deviation of voxel; (8) CT total lung volume; (9) normal lung; (10) reticular score; and (11) evaluation of change on sequential scans. The Quantitative Lung Fibrosis (QLF) score measures the extent of reticular patterns with architectural distortion due to fibrosis using a support vector machine classifier. Range: 0 to 100. Higher scores imply greater impairment.
| score on a scale | Belumosudil-R | BSC-R | Belumosudil-WC | BSC-NC | Total |
|---|---|---|---|---|---|
| Baseline | 30.91 ± 14.54 | 33.34 ± 17.81 | 31.78 ± 15.48 | 33.34 ± 17.81 | 32.53 ± 16.45 |
| Change at Week 24 | 7.36 ± 11.46 | 1.08 ± 6.31 | 8.00 ± 12.55 | 1.41 ± 6.31 | 4.67 ± 10.44 |
| Change at Week 48 | 6.51 ± 11.76 | 6.23 ± 13.27 | 6.01 ± 11.74 | — | 6.06 ± 11.87 |
| Change at Week 96 | 6.36 ± 10.41 | 8.47 ± 21.86 | 6.36 ± 10.41 | — | 6.71 ± 12.09 |
The categorical changes of lung fibrosis using subjective visual assessments by radiologists from sequential scans at baseline, Week 24, Week 48, and Week 96. Changes were categorized as: (1) much better; (2) slightly better; (3) same; (4) slightly worse; and (5) much worse. This categorization is simplified as Better (Much or Slightly); Same; and Worse (Slightly or Much).
| Participants | Belumosudil-R | BSC-R | Belumosudil-WC | BSC-NC | Total |
|---|---|---|---|---|---|
| Week 24: Better | 0 | 1 | 1 | 1 | 1 |
| Week 24: Same | 22 | 13 | 25 | 11 | 35 |
| Week 24: Worse | 13 | 4 | 17 | 4 | 17 |
| Week 48: Better | 0 | 1 | 1 | — | 1 |
| Week 48: Same | 6 | 1 | 6 | — | 7 |
| Week 48: Worse | 10 | 5 | 13 | — | 15 |
| Week 96: Better | 0 | 1 | 1 | 0 | 1 |
| Week 96: Same | 1 | 0 | 1 | 0 | 1 |
| Week 96: Worse | 3 | 1 | 3 | — | 4 |
The change in Data-driven Texture Analysis (DTA) Lung Fibrosis mean score using sequential scans from Radiologist's Visual Reads from baseline to Weeks 24, 48, and 96. The change in DTA Lung Fibrosis mean score was measured using sequential scans from Radiologist's Visual Reads from baseline at Weeks 24, 48, and 96. DTA fibrosis score was computed as the number of Region of Interests (ROIs) classified as fibrotic divided by the total number of ROIs sampled from the lung segmentation volume. The DTA fibrosis score ranged from 0 - 100%, where higher scores indicated worsening of disease.
| units on a scale (0-100) | Belumosudil-R | BSC-R | Belumosudil-WC | BSC-NC | Total |
|---|---|---|---|---|---|
| Baseline | 23.1 ± 11.99 | 22.7 ± 10.77 | 22.3 ± 12.07 | 22.7 ± 10.77 | 22.5 ± 11.35 |
| Change at Week 24 | 0.3 ± 4.82 | 0.6 ± 4.29 | 1.2 ± 6.86 | 0.6 ± 4.43 | 0.9 ± 5.70 |
| Change at Week 48 | 3.1 ± 7.51 | 2.9 ± 4.88 | 2.9 ± 7.26 | — | 2.9 ± 6.44 |
| Change at Week 96 | 7.5 ± 9.57 | 5.0 ± 7.07 | 7.5 ± 9.57 | — | 6.7 ± 8.16 |
Acute exacerbation of IPF was defined by the following symptoms within 1 month that could not be explained by other reasons: (1) aggravated dyspnea; (2) newly discovered chest interstitial lung abnormality (by radiograph or HRCT); (3) SpO2 decrease to \< 88%. Acute exacerbation was diagnosed if Items #1 and #2 were present or if Items #1 and #3 were present and the following AEs did not occur: (A) any AE with the Preferred Term containing the word "infection" or "cardiac failure"; (B) pulmonary embolism; (C) pneumothorax.
| Event-free Probability | Belumosudil-R | Belumosudil-WC | BSC-NC |
|---|---|---|---|
| 24 weeks | 0.91 (0.78 to 0.97) | 0.91 (0.80 to 0.96) | 0.92 (0.54 to 0.99) |
| 48 weeks | 0.85 (0.70 to 0.93) | 0.84 (0.70 to 0.92) | — |
| 96 weeks | 0.64 (0.44 to 0.78) | 0.66 (0.48 to 0.79) | — |
Progression of IPF exacerbation was defined as the probability of a subject exhibiting IPF time from baseline to any of the following: (1) probability of first respiratory-related hospitalization; (2) probability of respiratory-related death; absolute decline in FVC% Predicted value of ≥ 10% vs. FVC %; probability of predicted value recorded at baseline; and (4) probability of absolute decline in DLCO, adjusted for hemoglobin (Hb), Percent of predicted value of ≥ 15% vs. DLCO at baseline. Subjects randomized to and received BSC were censored on crossover.
| Event-free Probability | Belumosudil-R | Belumosudil-WC | BSC-NC |
|---|---|---|---|
| 24 weeks | 0.86 (0.71 to 0.93) | 0.80 (0.67 to 0.88) | 0.66 (0.39 to 0.83) |
| 48 weeks | 0.52 (0.35 to 0.66) | 0.47 (0.33 to 0.60) | — |
| 96 weeks | 0.20 (0.09 to 0.35) | 0.16 (0.07 to 0.28) | — |
Probability of first-related hospitalization defined as any AE where the high-level group term contained the terms "respiratory" and the AE resulted in a hospitalization. Subjects randomized and received BSC were censored on crossover. Note: The hazard ratios for Belumosudil-R vs. BSC-NC and for Belumosudil-WC vs. BSC-NC were not calculable.
| Event-free Probability | Belumosudil-R | Belumosudil-WC |
|---|---|---|
| 24 weeks | 0.98 (0.85 to 1.00) | 0.96 (0.86 to 0.99) |
| 48 weeks | 0.89 (0.74 to 0.96) | 0.85 (0.72 to 0.93) |
| 96 weeks | 0.79 (0.61 to 0.90) | 0.75 (0.58 to 0.85) |
Probability of respiratory-related death, defined as any AE where the high-level group term contained the term "respiratory" and the AE resulted in a death. Subjects randomized to and who received BSC were censored on crossover.
| Event-free Probability | Belumosudil-R | Belumosudil-WC | BSC-NC |
|---|---|---|---|
| 24 weeks | 0.98 (0.85 to 1.00) | 0.98 (0.87 to 1.00) | 0.95 (0.69 to 0.99) |
| 48 weeks | 0.92 (0.76 to 0.97) | 0.91 (0.77 to 0.97) | — |
| 96 weeks | 0.88 (0.71 to 0.95) | 0.88 (0.72 to 0.95) | — |
The St. George's Respiratory Questionnaire (SGRQ) is a disease-specific instrument designed to measure impact on overall health, daily life, and perceived well-being in subjects with obstructive airways disease consisting of 2 parts: (1) symptoms component (frequency \& severity) with a 3-month recall; and (2) activities that cause or are limited by breathlessness. Impact components (social functioning, psychological disturbances resulting from airways disease) refer to current state as the recall. Changes were assessed from baseline at Week 24, at Week 48, and at Week 96. The SGRQ scores range from 0 to 100, with higher scores indicating greater limitations. Based on empirical data and interviews with subjects, a mean change score of 4 units is associated with slightly efficacious treatment, 8 units for moderately efficacious change, and 12 units for very efficacious treatment
| units on a scale | Belumosudil-R | BSC-R | Belumosudil-WC | BSC-NC | Total |
|---|---|---|---|---|---|
| Baseline | 64.45 ± 18.98 | 74.45 ± 18.94 | 64.86 ± 18.29 | 74.45 ± 18.94 | 68.63 ± 18.83 |
| Change at Week 24 | -5.78 ± 17.74 | -2.64 ± 9.59 | -2.63 ± 18.38 | -2.64 ± 9.59 | -2.64 ± 14.79 |
| Change at Week 48 | 0.36 ± 15.34 | 2.07 ± 9.90 | 0.41 ± 14.63 | — | 0.63 ± 13.93 |
| Change at Week 96 | 1.50 ± 16.61 | 9.35 ± 4.54 | 1.37 ± 15.76 | — | 2.60 ± 14.75 |
Collected over Subjects randomized to belumosudil 400 mg PO QD: up to 96 weeks of treatment Subjects randomized to BSC: 24 weeks of BSC plus up to 96 weeks of treatment with belumosudil 400 mg PO QD. Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Belumosudil-R | 7/51 (13.7%) | 29/51 (56.9%) | 50/51 (98%) |
| BSC-R | 3/24 (12.5%) | 10/24 (41.7%) | 23/24 (95.8%) |
| Belumosudil-WC | 9/68 (13.2%) | 38/68 (55.9%) | 67/68 (98.5%) |
| BSC-NC | 1/24 (4.2%) | 4/24 (16.7%) | 19/24 (79.2%) |
| Total | 10/75 (13.3%) | 39/75 (52%) | 73/75 (97.3%) |
| Event | Belumosudil-R | BSC-R | Belumosudil-WC | BSC-NC | Total |
|---|---|---|---|---|---|
| Acute respiratory failureRespiratory, thoracic and mediastinal disorders | 6/51 | 3/24 | 8/68 | 1/24 | 9/75 |
| DyspneaRespiratory, thoracic and mediastinal disorders | 5/51 | 1/24 | 6/68 | 0/24 | 6/75 |
| Acute myocardial infarction (AMI)Cardiac disorders | 1/51 | 2/24 | 2/68 | 1/24 | 3/75 |
| Atrial fibrillationCardiac disorders | 1/51 | 2/24 | 3/68 | 0/24 | 3/75 |
| PneumoniaInfections and infestations | 4/51 | 0/24 | 4/68 | 0/24 | 4/75 |
| Congestive cardiac failureCardiac disorders | 3/51 | 0/24 | 3/68 | 0/24 | 3/75 |
| Respiratory failureRespiratory, thoracic and mediastinal disorders | 1/51 | 1/24 | 2/68 | 0/24 | 2/75 |
| Acute respiratory distress syndromeRespiratory, thoracic and mediastinal disorders | 0/51 | 1/24 | 1/68 | 0/24 | 1/75 |
| Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders | 0/51 | 1/24 | 1/68 | 0/24 | 1/75 |
| Chronic respiratory failureRespiratory, thoracic and mediastinal disorders | 0/51 | 1/24 | 1/68 | 0/24 | 1/75 |
| Event | Belumosudil-R | BSC-R | Belumosudil-WC | BSC-NC | Total |
|---|---|---|---|---|---|
| DyspneaRespiratory, thoracic and mediastinal disorders | 19/51 | 5/24 | 21/68 | 4/24 | 24/75 |
| CoughRespiratory, thoracic and mediastinal disorders | 14/51 | 8/24 | 14/68 | 8/24 | 22/75 |
| DiarrheaGastrointestinal disorders | 12/51 | 6/24 | 18/68 | 0/24 | 18/75 |
| Upper respiratory tract infectionInfections and infestations | 5/51 | 6/24 | 8/68 | 4/24 | 11/75 |
| Viral upper respiratory tract infectionInfections and infestations | 8/51 | 5/24 | 11/68 | 2/24 | 13/75 |
| BronchitisInfections and infestations | 7/51 | 5/24 | 7/68 | 5/24 | 12/75 |
| NauseaGastrointestinal disorders | 6/51 | 4/24 | 8/68 | 3/24 | 10/75 |
| FatigueGeneral disorders | 7/51 | 4/24 | 11/68 | 1/24 | 11/75 |
| Back painMusculoskeletal and connective tissue disorders | 5/51 | 4/24 | 7/68 | 2/24 | 9/75 |
| Alanine aminotransferase (ALT) increasedInvestigations | 8/51 | 3/24 | 10/68 | 1/24 | 11/75 |
One subject randomized to belumosudil 400 mg PO QD did not receive study medication. Analysis was performed using the safety population that consisted of all subjects who were randomized and received ≥ 1 dose of belumosudil-R or, for subjects who had BSC, week 1 assessments. Available data at baseline have been reported.
| Age, Continuous(years) | Belumosudil 400 mg PO QD | BSC-R | Total |
|---|---|---|---|
| Mean | 72.5 ± 7.0 | 74.9 ± 5.9 | 73.3 ± 6.7 |
| Sex: Female, Male(Participants) | Belumosudil 400 mg PO QD | BSC-R | Total |
|---|---|---|---|
| Female | 13 | 6 | 19 |
| Male | 38 | 18 | 56 |
| Ethnicity (NIH/OMB)(Participants) | Belumosudil 400 mg PO QD | BSC-R | Total |
|---|---|---|---|
| Hispanic or Latino | 6 | 0 | 6 |
| Not Hispanic or Latino | 45 | 24 | 69 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Belumosudil 400 mg PO QD | BSC-R | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 2 | 0 | 2 |
| White | 49 | 24 | 73 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Prior Use of Pirfenidone(Participants) | Belumosudil 400 mg PO QD | BSC-R | Total |
|---|---|---|---|
| Yes | 13 | 4 | 17 |
| No | 38 | 20 | 58 |
| Prior Use of Nintedanib(Participants) | Belumosudil 400 mg PO QD | BSC-R | Total |
|---|---|---|---|
| Yes | 10 | 4 | 14 |
| No | 41 | 20 | 61 |
| Prior Use of Pirfenidone or Nintedanib(Participants) | Belumosudil 400 mg PO QD | BSC-R | Total |
|---|---|---|---|
| Yes | 19 | 6 | 25 |
| No | 32 | 18 | 50 |
| GAP Stage(Participants) | Belumosudil 400 mg PO QD | BSC-R | Total |
|---|---|---|---|
| Stage I | 11 | 7 | 18 |
| Stage II | 31 | 12 | 43 |
| Stage III | 9 | 5 | 14 |
3 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from May 2016 to primary completion in Apr 2021, 58 months.
Results were first posted in Sep 2022, 1 year 4 months after primary completion.
Of 63 industry-sponsored phase 2 interventional studies under Idiopathic Pulmonary Fibrosis, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 48. This study's 58 months is above that.
Counting every sponsor, half of 76 studies reached it within 30 months; a quarter within 21 and three quarters within 50.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Belumosudil
Idiopathic Pulmonary Fibrosis →